Global Autologous Matrix-induced Chondrogenesis Market Research Report 2023

Publication ID:

PB503236658

Publication Date:

March 16, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Autologous matrix-induced chondrogenesis听(AMIC) is a 1-step cartilage restoration technique that combines microfracture with the use of an exogenous scaffold.
Highlights
The global Autologous Matrix-induced Chondrogenesis market was valued at US$ 112.2 million in 2022 and is anticipated to reach US$ 149.5 million by 2029, witnessing a CAGR of 4.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The functional principle of microfracturing is based on the release of multipotent mesenchymal progenitor cells, cytokines and growth factors from the subchondral bone.听
Report Scope
This report aims to provide a comprehensive presentation of the global market for Autologous Matrix-induced Chondrogenesis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autologous Matrix-induced Chondrogenesis.
The Autologous Matrix-induced Chondrogenesis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Autologous Matrix-induced Chondrogenesis market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Autologous Matrix-induced Chondrogenesis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings
Segment by Type
Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Poly Lactic-Co-Glycolic Acid (PGLA)
Segment by Application
Knees Joint
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Autologous Matrix-induced Chondrogenesis companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Autologous Matrix-induced Chondrogenesis Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hyaluronic Acid
1.2.3 Collagen
1.2.4 Polyethylene Glycol (PEG)
1.2.5 Poly Lactic-Co-Glycolic Acid (PGLA)
1.3 Market by Application
1.3.1 Global Autologous Matrix-induced Chondrogenesis Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Knees Joint
1.3.3 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Autologous Matrix-induced Chondrogenesis Market Perspective (2018-2029)
2.2 Autologous Matrix-induced Chondrogenesis Growth Trends by Region
2.2.1 Global Autologous Matrix-induced Chondrogenesis Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Autologous Matrix-induced Chondrogenesis Historic Market Size by Region (2018-2023)
2.2.3 Autologous Matrix-induced Chondrogenesis Forecasted Market Size by Region (2024-2029)
2.3 Autologous Matrix-induced Chondrogenesis Market Dynamics
2.3.1 Autologous Matrix-induced Chondrogenesis Industry Trends
2.3.2 Autologous Matrix-induced Chondrogenesis Market Drivers
2.3.3 Autologous Matrix-induced Chondrogenesis Market Challenges
2.3.4 Autologous Matrix-induced Chondrogenesis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Autologous Matrix-induced Chondrogenesis Players by Revenue
3.1.1 Global Top Autologous Matrix-induced Chondrogenesis Players by Revenue (2018-2023)
3.1.2 Global Autologous Matrix-induced Chondrogenesis Revenue Market Share by Players (2018-2023)
3.2 Global Autologous Matrix-induced Chondrogenesis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Autologous Matrix-induced Chondrogenesis Revenue
3.4 Global Autologous Matrix-induced Chondrogenesis Market Concentration Ratio
3.4.1 Global Autologous Matrix-induced Chondrogenesis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Autologous Matrix-induced Chondrogenesis Revenue in 2022
3.5 Autologous Matrix-induced Chondrogenesis Key Players Head office and Area Served
3.6 Key Players Autologous Matrix-induced Chondrogenesis Product Solution and Service
3.7 Date of Enter into Autologous Matrix-induced Chondrogenesis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Autologous Matrix-induced Chondrogenesis Breakdown Data by Type
4.1 Global Autologous Matrix-induced Chondrogenesis Historic Market Size by Type (2018-2023)
4.2 Global Autologous Matrix-induced Chondrogenesis Forecasted Market Size by Type (2024-2029)
5 Autologous Matrix-induced Chondrogenesis Breakdown Data by Application
5.1 Global Autologous Matrix-induced Chondrogenesis Historic Market Size by Application (2018-2023)
5.2 Global Autologous Matrix-induced Chondrogenesis Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
6.2 North America Autologous Matrix-induced Chondrogenesis Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Autologous Matrix-induced Chondrogenesis Market Size by Country (2018-2023)
6.4 North America Autologous Matrix-induced Chondrogenesis Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
7.2 Europe Autologous Matrix-induced Chondrogenesis Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Autologous Matrix-induced Chondrogenesis Market Size by Country (2018-2023)
7.4 Europe Autologous Matrix-induced Chondrogenesis Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
8.2 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Size by Region (2018-2023)
8.4 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
9.2 Latin America Autologous Matrix-induced Chondrogenesis Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Autologous Matrix-induced Chondrogenesis Market Size by Country (2018-2023)
9.4 Latin America Autologous Matrix-induced Chondrogenesis Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
10.2 Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Size by Country (2018-2023)
10.4 Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 JRI Orthopaedics Ltd
11.1.1 JRI Orthopaedics Ltd Company Detail
11.1.2 JRI Orthopaedics Ltd Business Overview
11.1.3 JRI Orthopaedics Ltd Autologous Matrix-induced Chondrogenesis Introduction
11.1.4 JRI Orthopaedics Ltd Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.1.5 JRI Orthopaedics Ltd Recent Development
11.2 BioTissue
11.2.1 BioTissue Company Detail
11.2.2 BioTissue Business Overview
11.2.3 BioTissue Autologous Matrix-induced Chondrogenesis Introduction
11.2.4 BioTissue Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.2.5 BioTissue Recent Development
11.3 Anika Therapeutics
11.3.1 Anika Therapeutics Company Detail
11.3.2 Anika Therapeutics Business Overview
11.3.3 Anika Therapeutics Autologous Matrix-induced Chondrogenesis Introduction
11.3.4 Anika Therapeutics Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.3.5 Anika Therapeutics Recent Development
11.4 B. Braun Melsungen
11.4.1 B. Braun Melsungen Company Detail
11.4.2 B. Braun Melsungen Business Overview
11.4.3 B. Braun Melsungen Autologous Matrix-induced Chondrogenesis Introduction
11.4.4 B. Braun Melsungen Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.4.5 B. Braun Melsungen Recent Development
11.5 Arthro-Kinetics
11.5.1 Arthro-Kinetics Company Detail
11.5.2 Arthro-Kinetics Business Overview
11.5.3 Arthro-Kinetics Autologous Matrix-induced Chondrogenesis Introduction
11.5.4 Arthro-Kinetics Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.5.5 Arthro-Kinetics Recent Development
11.6 Geistlich Pharma
11.6.1 Geistlich Pharma Company Detail
11.6.2 Geistlich Pharma Business Overview
11.6.3 Geistlich Pharma Autologous Matrix-induced Chondrogenesis Introduction
11.6.4 Geistlich Pharma Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.6.5 Geistlich Pharma Recent Development
11.7 CartiHeal
11.7.1 CartiHeal Company Detail
11.7.2 CartiHeal Business Overview
11.7.3 CartiHeal Autologous Matrix-induced Chondrogenesis Introduction
11.7.4 CartiHeal Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.7.5 CartiHeal Recent Development
11.8 Matricel
11.8.1 Matricel Company Detail
11.8.2 Matricel Business Overview
11.8.3 Matricel Autologous Matrix-induced Chondrogenesis Introduction
11.8.4 Matricel Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.8.5 Matricel Recent Development
11.9 Smith & Nephew
11.9.1 Smith & Nephew Company Detail
11.9.2 Smith & Nephew Business Overview
11.9.3 Smith & Nephew Autologous Matrix-induced Chondrogenesis Introduction
11.9.4 Smith & Nephew Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.9.5 Smith & Nephew Recent Development
11.10 Zimmer Biomet Holdings
11.10.1 Zimmer Biomet Holdings Company Detail
11.10.2 Zimmer Biomet Holdings Business Overview
11.10.3 Zimmer Biomet Holdings Autologous Matrix-induced Chondrogenesis Introduction
11.10.4 Zimmer Biomet Holdings Revenue in Autologous Matrix-induced Chondrogenesis Business (2018-2023)
11.10.5 Zimmer Biomet Holdings Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂